C-peptide Blood Test Explained: What It Measures and Why It's Ordered

This page is for educational purposes only and is not medical advice; consult a licensed physician about any laboratory test, result or symptom. Nothing here interprets an individual result, and no reference ranges are offered as guidance — reference intervals are assay-specific and belong with the ordering clinician and the reporting laboratory.

What C-peptide is and where it comes from

C-peptide — the "connecting peptide" — is a 31-amino-acid fragment of the proinsulin molecule. A biochemistry review described how beta cells of the pancreatic islets synthesise preproinsulin, process it to proinsulin, and then cleave proinsulin into insulin and C-peptide, which are stored in secretory granules and released into the portal circulation in equimolar amounts (https://pubmed.ncbi.nlm.nih.gov/30252282/). That equimolar co-secretion is the reason C-peptide is used as a proxy for how much insulin a person's own beta cells are making.

The same review noted the practical advantage that makes C-peptide attractive to laboratories: insulin undergoes substantial first-pass extraction by the liver, whereas C-peptide is cleared mainly by the kidney and has a longer circulating half-life, so peripheral C-peptide concentrations track secretion more faithfully than peripheral insulin does (https://pubmed.ncbi.nlm.nih.gov/30252282/). A clinical perspective on C-peptide determination made the same point, describing C-peptide as the preferred circulating marker of endogenous insulin secretion in routine practice (https://pubmed.ncbi.nlm.nih.gov/35676794/).

What the test actually measures

Laboratory guidelines for the diagnosis and management of diabetes described C-peptide as measured in serum or plasma by immunoassay, with results reported in molar units (nmol/L) or mass units (ng/mL) depending on the laboratory (https://pubmed.ncbi.nlm.nih.gov/37471273/). The companion publication of those guidelines in the clinical chemistry literature set out the same analytical framework, including the point that assay standardisation and between-method variability remain live issues for C-peptide measurement (https://pubmed.ncbi.nlm.nih.gov/37473453/).

Specimen types described in the literature

• Random (non-fasting) serum or plasma C-peptide, usually paired with a simultaneous glucose, which the clinical review described as a pragmatic approach in diabetes classification because an uninterpretable low value in the presence of low glucose can be avoided (https://pubmed.ncbi.nlm.nih.gov/35676794/).
• Fasting C-peptide, which the clinical utility review discussed alongside stimulated testing as a measure of beta-cell reserve (https://pubmed.ncbi.nlm.nih.gov/23413806/).
• Stimulated C-peptide after a mixed-meal or glucagon challenge, which the same review described as the more standardised research measure of residual beta-cell function (https://pubmed.ncbi.nlm.nih.gov/23413806/).
• Urine C-peptide, which the clinical perspective reviewed as a non-invasive alternative that reflects integrated secretion over a collection period (https://pubmed.ncbi.nlm.nih.gov/35676794/).

Because C-peptide and insulin are released together, researchers have also used frequent C-peptide sampling to study the pulsatile nature of insulin secretion; a methodology review described deconvolution of peripheral C-peptide concentrations as a way to reconstruct pancreatic secretion rates, noting that such protocols require closely spaced sampling and careful modelling (https://pubmed.ncbi.nlm.nih.gov/34206296/). That is a research application rather than a routine clinical one.

Why clinicians order a C-peptide test, as described in the literature

Classifying the type of diabetes

The clinical perspective review reported that C-peptide measurement helps distinguish severe endogenous insulin deficiency — the pattern typical of type 1 diabetes and of long-standing insulin-treated disease — from preserved secretion seen in type 2 diabetes and in monogenic forms, and that this classification can influence treatment decisions such as whether insulin therapy is required (https://pubmed.ncbi.nlm.nih.gov/35676794/). The earlier clinical utility review described similar use of C-peptide to reassess diabetes classification when the original label does not fit the clinical course (https://pubmed.ncbi.nlm.nih.gov/23413806/).

Assessing residual beta-cell function

The clinical utility review reported that C-peptide — particularly stimulated C-peptide — is the standard measure of residual beta-cell function and has been used both in clinical care and as an endpoint in intervention studies in type 1 diabetes (https://pubmed.ncbi.nlm.nih.gov/23413806/). Laboratory guidelines likewise positioned C-peptide as the analyte used to document endogenous secretion in insulin-treated patients, where insulin assays cannot separate injected from secreted hormone (https://pubmed.ncbi.nlm.nih.gov/37473453/).

Investigating hypoglycaemia

C-peptide is central to the work-up of low blood glucose. A review of hyperinsulinaemic hypoglycaemia in adults described the diagnostic logic of measuring insulin, C-peptide and proinsulin during a documented hypoglycaemic episode to establish whether insulin secretion was inappropriately sustained, as occurs with insulinoma (https://pubmed.ncbi.nlm.nih.gov/15122101/). A review of factitious hypoglycaemia described the classic discordance used to detect surreptitious insulin administration: high insulin with suppressed C-peptide, because exogenous insulin contains no C-peptide and suppresses endogenous secretion, while sulfonylurea ingestion instead raises both insulin and C-peptide (https://pubmed.ncbi.nlm.nih.gov/31194450/).

A systematic review of insulin autoimmune syndrome described another cause of hyperinsulinaemic hypoglycaemia, in which insulin autoantibodies produce markedly elevated measured insulin and elevated C-peptide, and noted that antibody interference complicates immunoassay interpretation in these patients (https://pubmed.ncbi.nlm.nih.gov/36844104/).

High and low C-peptide: what published studies associate with each pattern

The literature frames C-peptide results as patterns to be read together with a simultaneous glucose, not as isolated numbers. The table below summarises what the cited reviews associated with each direction.

Elevated C-peptide has also appeared in the pregnancy literature as a marker of insulin resistance and hyperinsulinaemia; a review of gestational diabetes mellitus described the physiological insulin resistance of pregnancy and the compensatory increase in insulin secretion that accompanies it (https://pubmed.ncbi.nlm.nih.gov/19015764/).

Assay and pre-analytical caveats researchers have reported

Standardisation and method differences

Laboratory guidelines reported that C-peptide immunoassays differ in antibody specificity, calibration and cross-reactivity with proinsulin, so results are not freely interchangeable between methods and laboratories (https://pubmed.ncbi.nlm.nih.gov/37471273/). The clinical chemistry version of the same guidance emphasised the need for harmonisation and for laboratories to report method-specific reference intervals (https://pubmed.ncbi.nlm.nih.gov/37473453/).

Haemolysis

A laboratory study of haemolysis reported that haemolysed specimens interfered with C-peptide immunoassay results, consistent with degradation of the peptide by red-cell contents, and concluded that haemolysed samples are unsuitable for C-peptide measurement (https://pubmed.ncbi.nlm.nih.gov/27231209/). That is one reason laboratories reject such tubes rather than report a number.

Sample handling and stability

A stability study of 81 analytes in whole blood, serum and plasma examined how storage conditions and delays before separation affected measured concentrations across a broad analyte panel, underlining why laboratories specify handling and centrifugation timing for peptide analytes (https://pubmed.ncbi.nlm.nih.gov/22285385/).

Physiological context

The clinical perspective review stressed that a C-peptide value is uninterpretable without a simultaneous glucose, since secretion falls appropriately when glucose is low and rises when glucose is high (https://pubmed.ncbi.nlm.nih.gov/35676794/). The clinical utility review added that renal impairment, recent glycaemic control and the timing of the sample relative to meals all shape the result (https://pubmed.ncbi.nlm.nih.gov/23413806/). Antibody interference, described in the insulin autoimmune syndrome review, is a further source of spurious values (https://pubmed.ncbi.nlm.nih.gov/36844104/).

C-peptide Testing: What Studies Report About Limitations

C-peptide measurement is a blood draw, so the procedural risks are those of venepuncture rather than of the analyte itself. The limitations reported in the literature are analytical and interpretive. Laboratory guidelines reported method-dependent variability that can shift a result across a decision threshold (https://pubmed.ncbi.nlm.nih.gov/37471273/); the haemolysis study reported assay interference in damaged specimens (https://pubmed.ncbi.nlm.nih.gov/27231209/); and the systematic review of insulin autoimmune syndrome reported that autoantibodies can distort insulin and C-peptide immunoassay results in patients being investigated for hypoglycaemia (https://pubmed.ncbi.nlm.nih.gov/36844104/). Researchers in the factitious hypoglycaemia review also noted that the insulin-to-C-peptide pattern must be read against the drug history, since sulfonylureas mimic endogenous hyperinsulinism (https://pubmed.ncbi.nlm.nih.gov/31194450/).

How the literature frames interpretation

Across the cited reviews, C-peptide is presented as a contextual test rather than a standalone number. The clinical perspective review reported that its value comes from combining it with glucose, clinical history, duration of diabetes, autoantibody status and renal function (https://pubmed.ncbi.nlm.nih.gov/35676794/), and laboratory guidelines reported that cut-offs are method- and laboratory-specific (https://pubmed.ncbi.nlm.nih.gov/37473453/). For that reason this page does not list numeric ranges and does not evaluate any individual result; the clinician who ordered the test and the laboratory that performed it hold the information needed to interpret it.

References

• Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (Diabetes Care, 2023)
• Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (Clinical Chemistry, 2023)
• Biochemistry, C Peptide (StatPearls, 2023)
• C-peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective (Diabetes, Obesity & Metabolism, 2022)
• The clinical utility of C-peptide measurement in the care of patients with diabetes (Diabetic Medicine, 2013)
• Factitious Hypoglycemia (StatPearls, 2023)
• Hyperinsulinemic hypoglycemia in adults (Annales d'Endocrinologie, 2004)
• Insulin Autoimmune Syndrome: A Systematic Review (International Journal of Endocrinology, 2023)
• Gestational diabetes mellitus (Reviews in Obstetrics & Gynecology, 2008)
• Hemolysis Affects C-Peptide Immunoassay (Journal of Clinical Laboratory Analysis, 2016)
• Measurement of Pulsatile Insulin Secretion: Rationale and Methodology (Metabolites, 2021)
• Stability study of 81 analytes in human whole blood, in serum and in plasma (Clinical Biochemistry, 2012)